Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bryskier

Showing results (21-30 of 107) with videos related to

Pageof 11
Sort By:
Antimicrobial Agents and Chemotherapy|April 29, 1998
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine)J E Hoppe, A Bryskier
Pathologie-Biologie|June 1, 1985
[Cefpirome (HR 810). A new broad spectrum cephalosporin]A Bryskier, J F Chantot
Presse Medicale (Paris, France : 1983)|December 3, 1994
[Macrolides. New therapeutic prospects]A Bryskier, M T Labro
The Journal of Antimicrobial Chemotherapy|October 1, 1985
Antibacterial activity of ofloxacin and other 4-quinolone derivatives: in-vitro and in-vivo comparisonJ F Chantot, A Bryskier
Antimicrobial Agents and Chemotherapy|August 17, 2002
Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebaeM Maurin, A Bryskier, D Raoult
Antimicrobial Agents and Chemotherapy|April 1, 1995
Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophagesN Rastogi, V Labrousse, A Bryskier
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris|November 18, 1980
[Septicemia due to polyresistant Staphylococcus aureus (author's transl)]J P Bonnardot, R Bonvoisin, A Bryskier
Journal of Chemotherapy (Florence, Italy)|April 15, 2005
In vitro evaluation of faropenem activity against anaerobic bacteriaJ Behra-Miellet, L Dubreuil, A Bryskier
Antimicrobial Agents and Chemotherapy|July 1, 1993
In vitro activity of roxithromycin against 16 species of atypical mycobacteria and effect of pH on its radiometric MICsN Rastogi, K S Goh, A Bryskier
Antimicrobial Agents and Chemotherapy|February 19, 2000
Effect of proinflammatory cytokines on the interplay between roxithromycin, HMR 3647, or HMR 3004 and human polymorphonuclear neutrophilsD Vazifeh, A Bryskier, M T Labro
Pageof 11

Showing results (21-30 of 107) with videos related to

Sort By:
Pageof 11
Antimicrobial Agents and Chemotherapy|April 29, 1998
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine)J E Hoppe, A Bryskier
Pathologie-Biologie|June 1, 1985
[Cefpirome (HR 810). A new broad spectrum cephalosporin]A Bryskier, J F Chantot
Presse Medicale (Paris, France : 1983)|December 3, 1994
[Macrolides. New therapeutic prospects]A Bryskier, M T Labro
The Journal of Antimicrobial Chemotherapy|October 1, 1985
Antibacterial activity of ofloxacin and other 4-quinolone derivatives: in-vitro and in-vivo comparisonJ F Chantot, A Bryskier
Antimicrobial Agents and Chemotherapy|August 17, 2002
Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebaeM Maurin, A Bryskier, D Raoult
Antimicrobial Agents and Chemotherapy|April 1, 1995
Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophagesN Rastogi, V Labrousse, A Bryskier
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris|November 18, 1980
[Septicemia due to polyresistant Staphylococcus aureus (author's transl)]J P Bonnardot, R Bonvoisin, A Bryskier
Journal of Chemotherapy (Florence, Italy)|April 15, 2005
In vitro evaluation of faropenem activity against anaerobic bacteriaJ Behra-Miellet, L Dubreuil, A Bryskier
Antimicrobial Agents and Chemotherapy|July 1, 1993
In vitro activity of roxithromycin against 16 species of atypical mycobacteria and effect of pH on its radiometric MICsN Rastogi, K S Goh, A Bryskier
Antimicrobial Agents and Chemotherapy|February 19, 2000
Effect of proinflammatory cytokines on the interplay between roxithromycin, HMR 3647, or HMR 3004 and human polymorphonuclear neutrophilsD Vazifeh, A Bryskier, M T Labro
Pageof 11